特异性免疫治疗(SIT)旨在通过降低气道的高反应性,从而达到抗气道慢性炎症的效应,是针对哮喘病因的特异性治疗。我院从1996年开展此项工作,先后诊治过敏性支气管哮喘64例,疗效显著,现报告如下。 1 临床资料 1.1 病例选择:64例均符合1997年中华医学会制定的诊断标准。选择过敏性支气管哮喘64例,其中男24例,女40例,年龄31～64岁,病程3个月～40年。均未合并其它严重心肺疾病,经一般解痉,平喘、抗炎等对症治疗1个月以上效果差或反复发作。治疗前1周停用糖皮质激素及其它药物治疗。 1.2 方法 1.2.1 关于皮试情况:皮试抗原种类、皮试方法、试剂浓度的配制均按文献中方法进行,以太原制药 Specific immunotherapy (SIT) is a specific treatment for the etiology of asthma by reducing the airway hyperresponsiveness to achieve the effect of anti-airway chronic inflammation. Our hospital from 1996 to carry out this work, has diagnosed 64 cases of allergic bronchial asthma, a significant effect, are as follows. 1 clinical data 1.1 Case Selection: 64 cases are in line with the 1997 Chinese Medical Association to develop diagnostic criteria. Select allergic bronchial asthma in 64 cases, including 24 males and 40 females, aged 31 to 64 years, duration of 3 months to 40 years. Have not combined with other serious heart and lung disease, the general antispasmodic, asthma, anti-inflammatory and other symptomatic treatment for more than 1 month poor or recurrent. Glucocorticoids and other medications were discontinued 1 week before treatment. 1.2 Methods 1.2.1 on the skin test cases: Skin test antigen species, skin test methods, reagent concentration preparation according to the literature method, Taiyuan Pharmaceutical